NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Nasus Pharma Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026
$3.21+0.02 (+0.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Nasus Pharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
3 buys · 0 sales
Net bought $61.81K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ma-Weaver Jacob | 612,913 | 5.20% | 13G (passive) | Mar 31, 2026 |
| Capital Point Ltd. | 575,129 | 6.35% | 13G (passive) | Aug 14, 2025 |
| Udi Gilboa | 1,901,311 | 21.10% | 13G (passive) | Sep 30, 2025 |
| Dr. Dalia Megiddo | 1,888,873 | 20.90% | 13G (passive) | Sep 30, 2025 |
| Dr. Ronnie Hershman | 1,383,512 | 15.30% | 13G (passive) | Sep 30, 2025 |
| Dames GP LLC | 1,169,910 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Balyasny Asset Management L.P. | 1,169,909 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brendan P. O'Grady | Chief Executive Officer, Director | – | – | Jul 31, 2026 |
| Dan Benjamin Teleman | Chief Executive Officer, Director | 163,541 | 1.81% | Jul 29, 2026 |
| Dalia Megiddo | Chief Development Officer, Director | 1,894,068 | 21.01% | Mar 27, 2026 |
| Oren Elmaliah | Interim CFO | – | – | Sep 23, 2026 |
| Eyal Rubin | Chief Financial Officer | – | – | Sep 21, 2026 |
| Sharon Shacham | Director | – | – | Mar 27, 2026 |
| David Silberman | Director | – | – | Mar 27, 2026 |
| Isaac Israel | Director | – | – | Mar 27, 2026 |
| Ronnie Hershman | Director | 1,338,463 | 14.85% | Mar 27, 2026 |
| Udi Gilboa | – | 1,924,476 | 21.35% | Mar 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dan Benjamin Teleman Chief Executive Officer, Director | Jun 17, 2026 | Buy | +6,550 | $3.10 | $20.31K | 163,541 |
| Dan Benjamin Teleman Chief Executive Officer, Director | Apr 22, 2026 | Buy | +2,900 | $3.76 | $10.90K | 156,991 |
| Dan Benjamin Teleman Chief Executive Officer, Director | Mar 31, 2026 | Buy | +15,000 | $2.04 | $30.60K | 21,246 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.